LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence company, announced continued advancement of its mobile healthcare application ecosystem, including applications being prepared for anticipated future availability through the Apple App Store and Google Play Store. The company also revealed it has surpassed 1,000 early-stage platform subscribers, signaling growing interest in its telehealth and healthcare analytics platforms aimed at emerging markets, particularly Latin America.
The applications under development are designed to support telehealth, healthcare communication, patient engagement, provider coordination, emergency response, and AI-assisted healthcare initiatives. Management stated that development, testing, integration, and platform optimization efforts are ongoing, with certain applications being readied for submission to the Apple App Store and Google Play Store following continued development, internal testing, platform review, and regulatory considerations.
Dr. Kevin Rodan Levy, CEO of LataMed AI Corp., emphasized the significance of surpassing 1,000 early-stage users, calling it an encouraging milestone as the company refines its digital healthcare infrastructure initiatives. He noted that the company aims to expand accessibility and healthcare connectivity through both Apple and Android mobile platforms.
The company's broader technology initiatives remain focused on scalable healthcare infrastructure solutions for underserved and developing markets where access to healthcare coordination, telehealth services, and digital healthcare tools may be limited or fragmented. LataMed AI believes that continued onboarding activity and user engagement will provide valuable operational feedback as development progresses.
Despite the progress, the company emphasized that the applications and related platform technologies remain under active development and have not yet been fully commercialized or broadly deployed. No assurance can be provided regarding the timing of any public release, App Store or Google Play availability, regulatory progression, commercialization initiatives, or operational success.
For more information, visit LataMed AI's website or review the company's filings with the U.S. Securities and Exchange Commission at SEC.gov.
